Loading stock data…
$48.73+0.63 (+1.31%)
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.
AnaptysBio, Inc. in the Healthcare sector is trading at $48.73 with a market capitalization of $1.5B. Wall Street consensus targets $87.25 (8 analysts), implying a +79.0% move over the next 12 months. The stock is currently 33% below its 52-week high of $72.36, remaining 2.5% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $25.56M↓ | $108.25M↑ | $76.32M↑ | $22.26M↓ | $27.77M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$34.64M↓ | $66.90M↑ | $34.70M↑ | -$26.17M↑ | -$27.54M |
| Net Income | -$52.88M↓ | $49.61M↑ | $15.11M↑ | -$38.63M↑ | -$39.33M |
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete wh...